The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $299,968 firm-fixed-price SBIR Phase I contract to Vitruvian Bio, LLC, a small disadvantaged, woman-owned business, to develop an electrochemical self-monitoring device for rapid nucleic acid-based testing of HIV-1. This contract, which has a completion date of July 31, 2025, is set aside for small businesses and is part of NIAID's efforts to support the research and development of innovative diagnostic technologies for infectious diseases. Vitruvian Bio's project focuses on creating a point-of-care solution for measuring HIV viral load and drug adherence, leveraging the company's expertise in advanced medical research and diagnostic technology development.
Generated 3/16/25, 12:54 AM